Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

ALPMF's expanding lineup of cancer drugs, including zolbetuximab, positions them for substantial market growth and potential appreciation.

Opens in a new tab or window The indication for sacituzumab govitecan (Trodelvy) in previously treated patients with locally advanced or metastatic urothelial cancer was withdrawn last month after ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV ™ (enfortumab vedotin, an antibody-drug conjugate ...

Padcev (enfortumab vedotin-ejfv) is a brand-name infusion prescribed for urothelial cancer (a type of bladder cancer). As with other drugs, Padcev can cause side effects, such as rash and hair loss.

This is the first perioperative IO regimen to show a significant improvement in overall survival versus standard-of-care in muscle-invasive bladder cancer. Together with the ongoing VOLGA phase 3 ...

The FDA has started a priority review of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin in bladder cancer, setting up a possible approval next March. The US regulator ...

Bladder cancer refers to the growth of a ... has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Bassel Nazha presented an ongoing phase II study investigating the combination of enfortumab vedotin and pembrolizumab for treating locally advanced or metastatic bladder cancer of variant histology.